{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["73"],"submitter":["Chang L"],"pubmed_abstract":["<h4>Background</h4>Rosai-Dorfman disease (RDD) is a rare heterogeneous histiocytic disorder lacking standardized first-line treatment.<h4>Methods</h4>This single-center, phase 2 prospective study enrolled 13 newly diagnosed and 10 recurrent RDD patients from June 2021 to March 2023 at Peking Union Medical College Hospital (Beijing, China). Lenalidomide 25 mg days 1-21 plus dexamethasone 40 mg days 1, 8, 15, 22 was administered in 28-day cycles, totaling 12 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response rate (ORR) to lenalidomide and dexamethasone (RD) regimen, toxicity, and overall survival (OS) measured from RD start to death or last follow-up. OS and PFS were estimated according to Kaplan-Meier survival analysis and compared wi"],"journal":["EClinicalMedicine"],"pagination":["102685"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11253284"],"repository":["biostudies-literature"],"pubmed_title":["Lenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospective phase 2 study."],"pmcid":["PMC11253284"],"pubmed_authors":["Zhou DB","Lang M","Cao XX","Chang L","Liu ZZ","Lin H","Liu T","Cai H"],"additional_accession":[]},"is_claimable":false,"name":"Lenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospective phase 2 study.","description":"<h4>Background</h4>Rosai-Dorfman disease (RDD) is a rare heterogeneous histiocytic disorder lacking standardized first-line treatment.<h4>Methods</h4>This single-center, phase 2 prospective study enrolled 13 newly diagnosed and 10 recurrent RDD patients from June 2021 to March 2023 at Peking Union Medical College Hospital (Beijing, China). Lenalidomide 25 mg days 1-21 plus dexamethasone 40 mg days 1, 8, 15, 22 was administered in 28-day cycles, totaling 12 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response rate (ORR) to lenalidomide and dexamethasone (RD) regimen, toxicity, and overall survival (OS) measured from RD start to death or last follow-up. OS and PFS were estimated according to Kaplan-Meier survival analysis and compared wi","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-02T11:51:39.15Z","creation":"2025-04-06T17:10:41.752Z"},"accession":"S-EPMC11253284","cross_references":{"pubmed":["39022796"],"doi":["10.1016/j.eclinm.2024.102685"]}}